Table 3.
2017 AASLD/IDSA HCV guidance: treatment of chronic hepatitis C
| GT | LED/SOF |
EBR/GZR |
3D, 2D |
DCV+SOF |
SOF/VEL |
SOF/VEL/VOX |
G/P |
SIM+SOF |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TN | PR fail | Non-NS5A or SOF fail | TN | PR fail | TN | PR fail | TN | PR fail | TN | PR fail | Non-NS5A or SOF fail | TN | PR fail | Non-NS5A or SOF fail | NS5A fail | TN | PR fail | PI+PEG fail | Non-NS5A or SOF fail | NS5A fail*** | TN | PR fail | ||
| 1b | CHC | 12 wk (8 w*) | 12 wk | 12 wk+R† | 12 wk | 12 wk | 3D, 12 wk | 3D, 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 8 wk | 8 wk | 12 wk | 12 wk | 16 w | 12 wk | 12 wk | |||
| CC | 12 wk | 12 wk+R | 12 wk | 12 wk | 3D, 12 wk | 3D, 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 16 w | |||||||||
| 1a | CHC | 12 wk (8 w*) | 12 wk | 12 wk+R† | 12 wk (16 wk+R if ras+) | 12 wk (16 wk+R if ras+) | 3D, 12 wk+R | 3D, 12 wk+R | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 8 wk | 8 wk | 12 wk | 12 wk | 16 w | 12 wk | 12 wk | |||
| CC | 12 wk | 12 wk+R | 12 wk (16 wk+R if ras+) | 12 wk (16 wk+R if ras+) | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 16 w | |||||||||||
| 2 | CHC | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk (SOF fail) | 8 wk | 8 wk | 12 wk (SOF fail) | |||||||||||||||
| CC | 16–24 wk | 16–24 wk | 12 wk | 12 wk | 12 wk (SOF fail) | 12 wk | 12 wk | 12 wk (SOF fail) | ||||||||||||||||
| 3 | CHC | 12 wk | 12 wk (add R if RAS) | 12 wk | 12 wk (add R if RAS) | 12 wk (if Y93) | 12 wk | 12 wk | 8 wk | 16 wk | ||||||||||||||
| CC | 12 wk+SOF | 24 wk±R (if RAS, add R) | 12 wk (add R if RAS) | 12 wk+R | 12 wk (if Y93) | 12 wk | 12 wk | 12 wk+R | 12 wk | 16 wk | ||||||||||||||
| 4 | CHC | 12 wk | 12 wk | 12 wk | 12 wk (relapse), 16 wk (on treat fail**) | 2D, 12 wk+R | 2D, 12 wk+R | NR | NR | 12 wk | 12 wk | 12 wk | 12 wk | 8 wk | 8 wk | |||||||||
| CC | 12 wk | 12 wk+R | 12 wk | 12 wk (relapse), 16 wk (on treat fail**) | 2D, 12 wk+R | 2D, 12 wk+R | NR | NR | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | ||||||||||
| 5,6 | CHC | 12 wk | 12 wk | NR | NR | 12 wk | 12 wk | 12 wk | 12 wk | 8 wk | 8 wk | |||||||||||||
| CC | 12 wk | 12 wk | NR | NR | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | ||||||||||||||
CHC, chronic hepatitis; CC, compensated liver cirrhosis; TN, treatment-naïve; PI, NS3/4A protease inhibitor; PR fail, PEG-interferon alpha plus ribavirin fail; RASs, resistance associated substitutions; wk, weeks; LED/SOF, Ledipasvir/sofosbuvir; EBR/GZR, elbasvir/grazoprevir; 3D(OPr+D), ombitasvir/paritaprevir/ritonavir+dasabuvir; 2D(OPr), ombitasvir/paritaprevir/ritonavir; DCV, daclatasvir; SOF, sofosbuvir; SIM, simeprevir; VEL, velpatasvir; R, ribavirin; G/P, glecaprevir/pibrentasvir; VOX, voxilaprevir.
If Non-LC and HCV RNA <6×106 IU/mL and non-HIV infected;
Not indicated in SIM fail;
On treatment failure including failure to suppress and breakthrough;
Except NS3/4 protease inhibitor inclusive DAA regimen, NR: not recommended, The shaded part indicated the difference between 2017 KASL and and 2017 AASLD/IDSA.